Sponsor content
208 result(s) found, displaying 51 to 60
-
Australian public assessment report (AusPar)AusPAR for Exkivity (Mobocertinib) for treatment of patients with locally advanced or metastatic non-small lung cancer.
-
Designation or determinationOrphan drug
-
Prescription medicine decision summaryLivtencity (maribavir) is approved to treat cytomegalovirus (CMV).
-
Prescription medicine registrationActive ingredients: maribavir.
-
Designation or determinationOrphan drug
-
Cancellation by sponsorRequested by Takeda Pharmaceuticals Australia Pty Ltd
-
Cancellation by sponsorRequested by Takeda Pharmaceuticals Australia Pty Ltd
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for Mesalazine 1.2 TAKEDA (mesalazine) 1.2 g prolonged release tablet blister pack.
-
Prescription medicine decision summaryTGA decision: Exkivity (mobocertinib) is approved to treat lung cancer
-
Prescription medicine registrationActive ingredients: mobocertinib succinate.